Unknown

Dataset Information

0

TROP2 methylation and expression in tamoxifen-resistant breast cancer.


ABSTRACT:

Background

The DNA methyltransferase 1 inhibitor, 5-Aza-2'-deoxycytidine (5-Aza-dC) is a potential treatment for breast cancer. However, not all breast tumors will respond similarly to treatment with 5-Aza-dC, and little is known regarding the response of hormone-resistant breast cancers to 5-Aza-dC.

Methods

We demonstrate that 5-Aza-dC-treatment has a stronger effect on an estrogen receptor-negative, Tamoxifen-selected cell line, TMX2-28, than on the estrogen receptor-positive, MCF7, parental cell line. Using data obtained from the HM450 Methylation Bead Chip, pyrosequencing, and RT-qPCR, we identified a panel of genes that are silenced by promoter methylation in TMX2-28 and re-expressed after treatment with 5-Aza-dC.

Results

One of the genes identified, tumor associated calcium signal transducer 2 (TACSTD2), is altered by DNA methylation, and there is evidence that in some cancers decreased expression may result in greater proliferation. Analysis of DNA methylation of TACSTD2 and protein expression of its product, trophoblast antigen protein 2 (TROP2), was extended to a panel of primary (n?=?34) and recurrent (n?=?34) breast tumors. Stratifying tumors by both recurrence and ER status showed no significant relationship between TROP2 levels and TACSTD2 methylation. Knocking down TACSTD2 expression in MCF7 increased proliferation however; re-expressing TACSTD2 in TMX2-28 did not inhibit proliferation, indicating that TACSTD2 re-expression alone was insufficient to explain the decreased proliferation observed after treatment with 5-Aza-dC.

Conclusions

These results illustrate the complexity of the TROP2 signaling network. However, TROP2 may be a valid therapeutic target for some cancers. Further studies are needed to identify biomarkers that indicate how TROP2 signaling affects tumor growth and whether targeting TROP2 would be beneficial to the patient.

SUBMITTER: Zimmers SM 

PROVIDER: S-EPMC6034260 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

TROP2 methylation and expression in tamoxifen-resistant breast cancer.

Zimmers Stephanie M SM   Browne Eva P EP   Williams Kristin E KE   Jawale Rahul M RM   Otis Christopher N CN   Schneider Sallie S SS   Arcaro Kathleen F KF  

Cancer cell international 20180706


<h4>Background</h4>The DNA methyltransferase 1 inhibitor, 5-Aza-2'-deoxycytidine (5-Aza-dC) is a potential treatment for breast cancer. However, not all breast tumors will respond similarly to treatment with 5-Aza-dC, and little is known regarding the response of hormone-resistant breast cancers to 5-Aza-dC.<h4>Methods</h4>We demonstrate that 5-Aza-dC-treatment has a stronger effect on an estrogen receptor-negative, Tamoxifen-selected cell line, TMX2-28, than on the estrogen receptor-positive, M  ...[more]

Similar Datasets

| S-ECPF-GEOD-22664 | biostudies-other
| S-EPMC3962540 | biostudies-literature
| S-EPMC3214732 | biostudies-literature
| S-EPMC8750403 | biostudies-literature
| S-ECPF-GEOD-14513 | biostudies-other
| S-ECPF-GEOD-28267 | biostudies-other
| S-ECPF-GEOD-17775 | biostudies-other
2016-05-25 | PXD001812 | Pride
| S-EPMC3306256 | biostudies-literature
| S-EPMC8371881 | biostudies-literature